Skip to main content

Vericel Value Stock - Dividend - Research Selection

Vericel

ISIN: US92346J1088 , WKN: A12FU4

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

Vericel Corporation, a commercial-stage biopharmaceutical company, researches, develops, manufactures, markets, and sells patient-specific expanded cellular therapies to repair and regenerate damaged tissues and organs. It markets autologous cell therapy products, including MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Carticel, an autologous chondrocyte implant for the repair of symptomatic cartilage defects of the femoral condyle caused by acute or repetitive trauma in patients that have inadequate response to a prior arthroscopic or other surgical repair procedure. The company also markets Epicel, a permanent skin replacement humanitarian use device for the treatment of patients with deep-dermal or full-thickness burns. In addition, it develops ixmyelocel-T, a patient-specific multicellular therapy that has completed Phase IIb clinical trial for the treatment of advanced heart failure due to ischemic dilated cardiomyopathy. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was founded in 1989 and is headquartered in Cambridge, Massachusetts.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Vericel : Presentation May 2025

2025-05-27
Advanced Therapies for the Sports Medicine & Severe Burn Care Markets CORPORATE PRESENTATION MAY 2025 Vericel is a Leader in Advanced...

Conestoga Capital Advisors Micro Cap Composite Q1 2025 Commentary

2025-05-16
The Conestoga Micro Cap Composite outperformed the Russell Microcap Growth Index in the first quarter of 2025. Click here to read the full commentary.

Vericel First Quarter 2025 Earnings: Misses Expectations

2025-05-10
Vericel ( NASDAQ:VCEL ) First Quarter 2025 Results Key Financial Results Revenue: US$52.6m (up 2.6% from 1Q 2024). Net...

Vericel Corp (VCEL) Q1 2025 Earnings Call Highlights: Record Revenue and Strategic Growth ...

2025-05-09
Despite a net loss, Vericel Corp (VCEL) showcases robust revenue growth and promising market opportunities with Macy Arthro and Nexarid.

Vericel Corporation 2025 Q1 - Results - Earnings Call Presentation

2025-05-08
The following slide deck was published by Vericel Corporation in conjunction with their 2025 Q1 earnings call.

Vericel Corporation (VCEL) Q1 2025 Earnings Conference Call Transcript

2025-05-08
Vericel Corporation. (NASDAQ:VCEL) Q1 2025 Earnings Conference Call May 8, 2025 8:30 AM ETCompany ParticipantsEric Burns - VP, Finance and IRNick Colangelo...

Vericel Corporation (VCEL) Reports Q1 Loss, Misses Revenue Estimates

2025-05-08
Vericel (VCEL) delivered earnings and revenue surprises of -155.56% and 2.73%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Vericel Corporation (VCEL): Among Stocks with Insanely High PE Ratios Insiders Are Selling

2025-05-08
We recently published a list of 10 Stocks with Insanely High PE Ratios Insiders Are Selling. In this article, we are going to take a look at where Vericel Corporation (NASDAQ:VCEL) stands against other stocks with insanely high PE ratios insiders are selling. The U.S. stock market has turned into a theater of extremes right […]

Vericel Reports First Quarter 2025 Financial Results and Raises Full-Year Profitability Guidance

2025-05-08
Record First Quarter MACI Revenue of $46.3 Million and First Quarter Total Revenue of $52.6 Million Approximately 400 MACI Arthro Surgeons Trained to Date, with Year-to-Date Biopsy Growth Over 30% for Trained Surgeons Second Quarter Total Revenue and MACI Revenue Growth Expected to be in the Low- to Mid-20% Range Full-Year 2025 Revenue Guidance Reaffirmed and Profitability Guidance Raised Conference Call Today at 8:30am Eastern Time CAMBRIDGE, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Vericel Corp

High Growth Tech Stocks To Watch In The US May 2025

2025-05-08
Over the last 7 days, the United States market has risen by 1.2%, and over the past 12 months, it is up by 7.7%, with earnings forecasted to grow by 14% annually. In this context of steady growth, identifying high-growth tech stocks involves assessing their potential for innovation and scalability in a dynamic market landscape.